X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Galapagos and BridGene aim to discover and develop new precision medicines against oncology targets by leveraging Galapagos’ expertise in small molecule drug discovery and translational research along with BridGene’s proprietary IMTAC™ chemoproteomics platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galapagos
Deal Size: $727.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024
Details:
The collaboration between BridGene and Takeda is based on BridGene's proprietary IMTAC™ chemoproteomics platform, which is used to identify targets and small molecules for Takeda to develop into therapeutic candidates for clinical development.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2023
Details:
Proceeds from the offering will be used to develop BridGene’s chemoproteomic platform IMTAC™, which enables the screening of small molecules against whole proteome or against a prioritized target in live cells to discover drug candidates and traditionally undruggable targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lapam Capital
Deal Size: $38.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
